Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
Explore why profitable hospitals command higher valuations and how variability in transaction databases impacts fair market value.
Explore how proposed Medicaid cuts could impact health care valuations, reimbursement models and financial stability across various provider segments.
Learn about the risks of profit tunneling in nursing homes and why fair market value transactions help ensure compliance and financial integrity.
Within the changing landscape of educational technology, schools face new risk factors that affect students, faculty and administrators.
Get ahead of the curve by looking back at emerging trends in 2024 that are likely to impact health care valuation in 2025 and beyond. Download Weaver Insights now.
The shortage of key health care providers is impacting health care services. We explore factors driving demand and how this affects valuations.
Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Companies looking to transform their operations through AI will need to guard against risk from vendors without a SOC 2 report. Learn more here.
Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.
